VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles | Zendy

Jane C. Davies | Zendy; Samuel M. Moskowitz | Zendy; Cynthia D. Brown | Zendy; Alex Horsley | Zendy; Marcus Mall | Zendy; Edward F. McKone | Zendy; Barry J. Plant | Zendy; Dario Prais | Zendy; Bonnie W. Ramsey | Zendy; Jennifer L. TaylorCousar | Zendy; Elizabeth Tullis | Zendy; Ahmet Uluer | Zendy; Charlotte McKee | Zendy; Sarah Robertson | Zendy; Rebecca A. Shilling | Zendy; C Simard | Zendy; Fredrick Van Goor | Zendy; David Waltz | Zendy; Fengjuan Xuan | Zendy; Timothy Young | Zendy; Steven M. Rowe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Author(s) -

Jane C. Davies,

Samuel M. Moskowitz,

Cynthia D. Brown,

Alex Horsley,

Marcus Mall,

Edward F. McKone,

Barry J. Plant,

Dario Prais,

Bonnie W. Ramsey,

Jennifer L. TaylorCousar,

Elizabeth Tullis,

Ahmet Uluer,

Charlotte McKee,

Sarah Robertson,

Rebecca A. Shilling,

C Simard,

Fredrick Van Goor,

David Waltz,

Fengjuan Xuan,

Timothy Young,

Steven M. Rowe

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1807119

Subject(s) - ivacaftor , allele , cystic fibrosis , medicine , genetics , biology , gene , cystic fibrosis transmembrane conductance regulator

The next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659-tezacaftor-ivacaftor), was developed to restore the function of Phe508del CFTR protein in patients with cystic fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research